Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.

ROCHE0 sitesDecember 17, 2008

ConditionsPatients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

DrugsAvastin

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.
Sponsor: ROCHE
Status: Active, not recruiting
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 17, 2008

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

ROCHE

Eligibility Criteria

Inclusion Criteria

•1\. Patients with histologically or cytologically confirmed diagnosis of rectal carcinoma, who are subject to surgery for rectal cancer and are considered to have benefit from pre\-operative combined chemo\-radiotherapy, (i.e.: stage cT3, cT4, fixative tumors, tumors primarily inoperable). 2\. Age \>\= 18 3\. ECOG Performance Status 0\-1 (Appendix III) 4\. Life expectancy of at least 12 weeks 5\. Measurable and/or evaluable lesions according to RECIST criteria 6\. Laboratory requirements: \` Neutrophils \>\= 1\.5 x 109/L and Platelets \>\= 100 x 109/L \` Total bilirubin \<\= 1\.5 time the upper\-normal limits (UNL) of the Institutional normal values and ASAT (SGOT) and/or ALAT (SGPT) \<\= 2\.5 x UNL, or \<\= 5 x UNL in case of liver metastases, alkaline phosphatase \<\= 2\.5 x UNL, \<\= 5 x UNL in case of liver metastases. \` Creatinine clearance \>50 mL/min or serum creatinine \<\= 1\.5 x UNL) \` Urine dipstick of proteinuria \<2\+. Patients discovered to have \>\= 2\+ proteinuria on dipstick urinalysis at baseline, should undergo a 24\-hour urine collection and must demonstrate \<\=1 g of protein/24 hr. 7\. Written informed consent. 8\. Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating Center.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

•1\. Prior radiotherapy or chemotherapy for rectal cancer. 2\. Untreated brain metastases or spinal cord compression or primary brain tumours. 3\. History or evidence upon physical examination of CNS disease unless adequately treated (e.g., seizure not controlled with standard medical therapy or history of stroke). 4\. History of inflammatory bowel disease and/or acute/subacute bowel occlusion. 5\. Serious, non\-healing wound, ulcer, or bone fracture. 6\. Evidence of bleeding diathesis or coagulopathy. 7\. Uncontrolled hypertension. 8\. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. 9\. Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes. 10\. Chronic, daily treatment with high\-dose aspirin (\>325 mg/day) or other medications known to predispose to gastrointestinal ulceration. 11\. Treatment with any investigational drug within 30 days prior to enrolment. 12\. Patients with known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications 13\. Other co\-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal and squamous cell carcinoma or cervical cancer in situ 14\. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. 15\. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication. 16\. Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non\-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.